Vasculitis & polymyalgia rheumatica
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (antibody-associated vasculitis (AAV)): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
Authors' conclusion
This SLR provides current evidence to inform the 2022 update of the EULAR recommendations for the management of AAV.
Study context
- Population
- Studies on treatment of GPA and MPA (AAV); PubMed, EMBASE and Cochrane library, 1 February 2015 to 25 February 202290 articles included
- Outcome
- Treatment of GPA and MPA (evidence synthesis, LoE as printed)
Main finding
As reported in the abstract
- Cyclophosphamide and rituximab (RTX) show similar efficacy for remission induction
- Level of evidence (LoE) 1a
- RTX is more effective in relapsing disease
- LoE 1b
- Glucocorticoid (GC) protocols with faster tapering result in similar remission rates but lower rates of serious infections
- LoE 1b
- Avacopan can be used to rapidly taper and replace GC
- LoE 1b
- Plasma exchange: meta-analyses of RCTs show reduced risk of end-stage kidney disease at 1 year but not during long-term follow-up
- LoE 1a
- RTX for maintenance of remission is associated with lower relapse rates vs AZA
- LoE 1b
- Prolonged maintenance treatment results in lower relapse rates for AZA and RTX
- LoE 1b
Original publication
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis. RMD Open. Published 21 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →